Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. Fundamental Analysis
Medexus Pharmaceuticals Inc. (MDP.TO) shows weak financial fundamentals with a PE ratio of -304.88, profit margin of -0.22%, and ROE of -0.46%. The company generates $0.1B in annual revenue with weak year-over-year growth of -4.18%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 16.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze MDP.TO's fundamental strength across five key dimensions:
Efficiency Score
WeakMDP.TO struggles to generate sufficient returns from assets.
Valuation Score
ModerateMDP.TO shows balanced valuation metrics.
Growth Score
ModerateMDP.TO shows steady but slowing expansion.
Financial Health Score
ExcellentMDP.TO maintains a strong and stable balance sheet.
Profitability Score
WeakMDP.TO struggles to sustain strong margins.
Key Financial Metrics
Is MDP.TO Expensive or Cheap?
P/E Ratio
MDP.TO trades at -304.88 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, MDP.TO's PEG of 2.96 indicates potential overvaluation.
Price to Book
The market values Medexus Pharmaceuticals Inc. at 1.40 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 3.61 times EBITDA. This is generally considered low.
How Well Does MDP.TO Make Money?
Net Profit Margin
For every $100 in sales, Medexus Pharmaceuticals Inc. keeps $-0.22 as profit after all expenses.
Operating Margin
Core operations generate 3.10 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-0.46 in profit for every $100 of shareholder equity.
ROA
Medexus Pharmaceuticals Inc. generates $-0.16 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Medexus Pharmaceuticals Inc. produces operating cash flow of $17.29M, showing steady but balanced cash generation.
Free Cash Flow
Medexus Pharmaceuticals Inc. generates strong free cash flow of $17.09M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.53 in free cash annually.
FCF Yield
MDP.TO converts 23.49% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-304.88
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.96
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.40
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.67
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.49
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.12
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.00
vs 25 benchmark
ROA
Return on assets percentage
-0.00
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How MDP.TO Stacks Against Its Sector Peers
| Metric | MDP.TO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -304.88 | 27.91 | Better (Cheaper) |
| ROE | -0.46% | 687.00% | Weak |
| Net Margin | -0.22% | -45285.00% (disorted) | Weak |
| Debt/Equity | 0.49 | 0.33 | Weak (High Leverage) |
| Current Ratio | 1.12 | 2795.76 | Neutral |
| ROA | -0.16% | -13557.00% (disorted) | Weak |
MDP.TO outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Medexus Pharmaceuticals Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
14.90%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
126.58%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
872.15%
Industry Style: Defensive, Growth, Innovation
High Growth